Otsuka Pharmaceutical Europe Ltd
🇧🇪Belgium
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 119
- Registration Number
- NCT03130478
- Locations
- 🇪🇸
Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Spain
🇪🇸Hospital Universitario de Álava, Alava, Spain
🇪🇸Hospital Fundación Alcorcón, Alcorcón, Spain
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 636
- Registration Number
- NCT03130465
- Locations
- 🇫🇷
Centre Psychotherapique Nancy, Laxou, France
🇫🇷Centre Hospitalier Esquirol, Limoges, France
🇫🇷H. Paul-Guiraud Clamart, Clamart, France
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 262
- Registration Number
- NCT03005769
- Locations
- 🇮🇹
Centro Salute Mentale, Ancona, Italy
🇮🇹SPDC ASST Spedali Civili, Brescia, Italy
🇮🇹Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 407
- Registration Number
- NCT02848521
- Locations
- 🇦🇹
LKH Villach, Villach, Austria
🇧🇪UZ Leuven/Gasthuisberg KUL, Leuven, Belgium
🇫🇷CHU Nimes - Hôpital CAREMEAU, Nimes, France
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
Completed
- Conditions
- CancerHyponatremiaSyndrome of Inappropriate ADH (SIADH) Secretion
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 69
- Registration Number
- NCT02573077
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
Completed
- Conditions
- HyponatremiaSyndrome of Inappropriate ADH (SIADH) Secretion
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT02548845
An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
Completed
- Conditions
- HyponatremiaSyndrome of Inappropriate ADH (SIADH) Secretion
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT02545101
Adacolumn in Refractory UC Patients Trial
Phase 4
Completed
- Conditions
- Ulcerative Colitis, Active Moderate
- Interventions
- Device: (GMA) Adsorptive Apheresis
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT01481142
- Locations
- 🇫🇷
Clinique Universitaire d'Hépato-Gastroentérologie, Grenoble cedex, France
© Copyright 2025. All Rights Reserved by MedPath